T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival
Background T cell immunoglobulin mucin‐3 (Tim‐3) was initially recognized as a pivotal immune checkpoint inhibitor that maintains immune homeostasis and tolerance. Recently, Tim‐3 has been demonstrated to play an important role in tumor‐associated immune suppression and aberrant Tim‐3 expression has...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2015-09, Vol.112 (4), p.430-435 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 435 |
|---|---|
| container_issue | 4 |
| container_start_page | 430 |
| container_title | Journal of surgical oncology |
| container_volume | 112 |
| creator | Yang, Meng Yu, Qinchao Liu, Jing Fu, Weiwei Cao, Yanwei Yu, Lun Shao, Shixiu Wang, Xinsheng Niu, Haitao Wang, Yonghua |
| description | Background
T cell immunoglobulin mucin‐3 (Tim‐3) was initially recognized as a pivotal immune checkpoint inhibitor that maintains immune homeostasis and tolerance. Recently, Tim‐3 has been demonstrated to play an important role in tumor‐associated immune suppression and aberrant Tim‐3 expression has been reported in several human malignancies. However, the role of Tim‐3 in bladder urothelial carcinoma (BUC) remains largely unknown. The present study aims to investigate Tim‐3 expression in BUC and analyze correlations with clinicopathologic outcomes and postoperative survival.
Methods
Tim‐3 protein expressions were detected in paraffin embedded sections from 100 patients with BUC by immunohistochemistry. Expressions were correlated with clinicopathologic outcomes and postoperative survival.
Results
Tim‐3 protein was over‐expressed in bladder cancer cells, tumor infiltrating lymphocytes and endothelial cells from patients with BUC. The expression levels of Tim‐3 were significantly correlated with advanced pathological grade and T stage. Moreover, another immune checkpoint molecule programmed death receptor‐1(PD‐1) was also over‐ expressed in BUC tissues and had a significant correlation with Tim‐3. Multivariate analysis showed that Tim‐3 expression, as well as PD‐1 expression was both independent predictors of disease‐free survival and overall survival in patients with BUC.
Conclusion
Tim‐3 over‐expression implies adverse clinical outcomes for BUC, which suggests it is a potential prognostic biomarker and a novel therapeutic target in BUC. J. Surg. Oncol. 2015; 112:430–435. © 2015 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/jso.24012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1716942144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1716942144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4612-d6b654ac54558a3edc92b017f18f2ec8c822f7494160fb89c93ff0075a0e94943</originalsourceid><addsrcrecordid>eNp1kUtP3DAUhS3UCqa0i_4BZKmbdhHwK07cXTXQaREPVR3o0nIch_HgxIMd8_gD_d31MMCiEqsrnfudo6t7APiI0T5GiBwso98nDGGyBSYYCV4IJOo3YJJ3pGCVQDvgXYxLhJAQnG2DHcIJL2nFJuDvvNDGOWj7Pg3-yvkmOTvAPmk7FBSa-1UwMVo_wKw2TrWtCTAFPy6Ms8pBrUImfa--wmk2Wu1Xalx456-shtqHYJwasz1CNbRQxei1fRTgnR0XMKZwa2-Vew_edspF8-Fp7oKL70fz6Y_i5Hz2c_rtpNCMY1K0vOElU7pkZVkralotSINw1eG6I0bXuiakq5hgmKOuqYUWtOsQqkqFjMgy3QWfN7mr4G-SiaPsbVw_QA3GpyhxhblgBLM1-uk_dOlTGPJ1a6oUFFEhMvVlQ-ngYwymk6tgexUeJEZyXY7M5cjHcjK795SYmt60L-RzGxk42AB31pmH15Pk8e_z58hi47BxNPcvDhWuJa9oVco_ZzN5ekl-zQ9nWB7Sf3kbqf4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1715930399</pqid></control><display><type>article</type><title>T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Yang, Meng ; Yu, Qinchao ; Liu, Jing ; Fu, Weiwei ; Cao, Yanwei ; Yu, Lun ; Shao, Shixiu ; Wang, Xinsheng ; Niu, Haitao ; Wang, Yonghua</creator><creatorcontrib>Yang, Meng ; Yu, Qinchao ; Liu, Jing ; Fu, Weiwei ; Cao, Yanwei ; Yu, Lun ; Shao, Shixiu ; Wang, Xinsheng ; Niu, Haitao ; Wang, Yonghua</creatorcontrib><description>Background
T cell immunoglobulin mucin‐3 (Tim‐3) was initially recognized as a pivotal immune checkpoint inhibitor that maintains immune homeostasis and tolerance. Recently, Tim‐3 has been demonstrated to play an important role in tumor‐associated immune suppression and aberrant Tim‐3 expression has been reported in several human malignancies. However, the role of Tim‐3 in bladder urothelial carcinoma (BUC) remains largely unknown. The present study aims to investigate Tim‐3 expression in BUC and analyze correlations with clinicopathologic outcomes and postoperative survival.
Methods
Tim‐3 protein expressions were detected in paraffin embedded sections from 100 patients with BUC by immunohistochemistry. Expressions were correlated with clinicopathologic outcomes and postoperative survival.
Results
Tim‐3 protein was over‐expressed in bladder cancer cells, tumor infiltrating lymphocytes and endothelial cells from patients with BUC. The expression levels of Tim‐3 were significantly correlated with advanced pathological grade and T stage. Moreover, another immune checkpoint molecule programmed death receptor‐1(PD‐1) was also over‐ expressed in BUC tissues and had a significant correlation with Tim‐3. Multivariate analysis showed that Tim‐3 expression, as well as PD‐1 expression was both independent predictors of disease‐free survival and overall survival in patients with BUC.
Conclusion
Tim‐3 over‐expression implies adverse clinical outcomes for BUC, which suggests it is a potential prognostic biomarker and a novel therapeutic target in BUC. J. Surg. Oncol. 2015; 112:430–435. © 2015 Wiley Periodicals, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.24012</identifier><identifier>PMID: 26265374</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; bladder urothelial carcinoma ; Case-Control Studies ; Female ; Follow-Up Studies ; Hepatitis A Virus Cellular Receptor 2 ; Humans ; Immunoenzyme Techniques ; Male ; Membrane Proteins - metabolism ; Middle Aged ; Neoplasm Grading ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local - metabolism ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; PD-1 ; Prognosis ; Survival Rate ; Tim-3 ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - pathology ; Urothelium - metabolism ; Urothelium - pathology</subject><ispartof>Journal of surgical oncology, 2015-09, Vol.112 (4), p.430-435</ispartof><rights>2015 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4612-d6b654ac54558a3edc92b017f18f2ec8c822f7494160fb89c93ff0075a0e94943</citedby><cites>FETCH-LOGICAL-c4612-d6b654ac54558a3edc92b017f18f2ec8c822f7494160fb89c93ff0075a0e94943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.24012$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.24012$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26265374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Yu, Qinchao</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Fu, Weiwei</creatorcontrib><creatorcontrib>Cao, Yanwei</creatorcontrib><creatorcontrib>Yu, Lun</creatorcontrib><creatorcontrib>Shao, Shixiu</creatorcontrib><creatorcontrib>Wang, Xinsheng</creatorcontrib><creatorcontrib>Niu, Haitao</creatorcontrib><creatorcontrib>Wang, Yonghua</creatorcontrib><title>T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background
T cell immunoglobulin mucin‐3 (Tim‐3) was initially recognized as a pivotal immune checkpoint inhibitor that maintains immune homeostasis and tolerance. Recently, Tim‐3 has been demonstrated to play an important role in tumor‐associated immune suppression and aberrant Tim‐3 expression has been reported in several human malignancies. However, the role of Tim‐3 in bladder urothelial carcinoma (BUC) remains largely unknown. The present study aims to investigate Tim‐3 expression in BUC and analyze correlations with clinicopathologic outcomes and postoperative survival.
Methods
Tim‐3 protein expressions were detected in paraffin embedded sections from 100 patients with BUC by immunohistochemistry. Expressions were correlated with clinicopathologic outcomes and postoperative survival.
Results
Tim‐3 protein was over‐expressed in bladder cancer cells, tumor infiltrating lymphocytes and endothelial cells from patients with BUC. The expression levels of Tim‐3 were significantly correlated with advanced pathological grade and T stage. Moreover, another immune checkpoint molecule programmed death receptor‐1(PD‐1) was also over‐ expressed in BUC tissues and had a significant correlation with Tim‐3. Multivariate analysis showed that Tim‐3 expression, as well as PD‐1 expression was both independent predictors of disease‐free survival and overall survival in patients with BUC.
Conclusion
Tim‐3 over‐expression implies adverse clinical outcomes for BUC, which suggests it is a potential prognostic biomarker and a novel therapeutic target in BUC. J. Surg. Oncol. 2015; 112:430–435. © 2015 Wiley Periodicals, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>bladder urothelial carcinoma</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hepatitis A Virus Cellular Receptor 2</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Male</subject><subject>Membrane Proteins - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>PD-1</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Tim-3</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urothelium - metabolism</subject><subject>Urothelium - pathology</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtP3DAUhS3UCqa0i_4BZKmbdhHwK07cXTXQaREPVR3o0nIch_HgxIMd8_gD_d31MMCiEqsrnfudo6t7APiI0T5GiBwso98nDGGyBSYYCV4IJOo3YJJ3pGCVQDvgXYxLhJAQnG2DHcIJL2nFJuDvvNDGOWj7Pg3-yvkmOTvAPmk7FBSa-1UwMVo_wKw2TrWtCTAFPy6Ms8pBrUImfa--wmk2Wu1Xalx456-shtqHYJwasz1CNbRQxei1fRTgnR0XMKZwa2-Vew_edspF8-Fp7oKL70fz6Y_i5Hz2c_rtpNCMY1K0vOElU7pkZVkralotSINw1eG6I0bXuiakq5hgmKOuqYUWtOsQqkqFjMgy3QWfN7mr4G-SiaPsbVw_QA3GpyhxhblgBLM1-uk_dOlTGPJ1a6oUFFEhMvVlQ-ngYwymk6tgexUeJEZyXY7M5cjHcjK795SYmt60L-RzGxk42AB31pmH15Pk8e_z58hi47BxNPcvDhWuJa9oVco_ZzN5ekl-zQ9nWB7Sf3kbqf4</recordid><startdate>20150915</startdate><enddate>20150915</enddate><creator>Yang, Meng</creator><creator>Yu, Qinchao</creator><creator>Liu, Jing</creator><creator>Fu, Weiwei</creator><creator>Cao, Yanwei</creator><creator>Yu, Lun</creator><creator>Shao, Shixiu</creator><creator>Wang, Xinsheng</creator><creator>Niu, Haitao</creator><creator>Wang, Yonghua</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20150915</creationdate><title>T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival</title><author>Yang, Meng ; Yu, Qinchao ; Liu, Jing ; Fu, Weiwei ; Cao, Yanwei ; Yu, Lun ; Shao, Shixiu ; Wang, Xinsheng ; Niu, Haitao ; Wang, Yonghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4612-d6b654ac54558a3edc92b017f18f2ec8c822f7494160fb89c93ff0075a0e94943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>bladder urothelial carcinoma</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hepatitis A Virus Cellular Receptor 2</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Male</topic><topic>Membrane Proteins - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>PD-1</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Tim-3</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urothelium - metabolism</topic><topic>Urothelium - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Yu, Qinchao</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Fu, Weiwei</creatorcontrib><creatorcontrib>Cao, Yanwei</creatorcontrib><creatorcontrib>Yu, Lun</creatorcontrib><creatorcontrib>Shao, Shixiu</creatorcontrib><creatorcontrib>Wang, Xinsheng</creatorcontrib><creatorcontrib>Niu, Haitao</creatorcontrib><creatorcontrib>Wang, Yonghua</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Meng</au><au>Yu, Qinchao</au><au>Liu, Jing</au><au>Fu, Weiwei</au><au>Cao, Yanwei</au><au>Yu, Lun</au><au>Shao, Shixiu</au><au>Wang, Xinsheng</au><au>Niu, Haitao</au><au>Wang, Yonghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2015-09-15</date><risdate>2015</risdate><volume>112</volume><issue>4</issue><spage>430</spage><epage>435</epage><pages>430-435</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
T cell immunoglobulin mucin‐3 (Tim‐3) was initially recognized as a pivotal immune checkpoint inhibitor that maintains immune homeostasis and tolerance. Recently, Tim‐3 has been demonstrated to play an important role in tumor‐associated immune suppression and aberrant Tim‐3 expression has been reported in several human malignancies. However, the role of Tim‐3 in bladder urothelial carcinoma (BUC) remains largely unknown. The present study aims to investigate Tim‐3 expression in BUC and analyze correlations with clinicopathologic outcomes and postoperative survival.
Methods
Tim‐3 protein expressions were detected in paraffin embedded sections from 100 patients with BUC by immunohistochemistry. Expressions were correlated with clinicopathologic outcomes and postoperative survival.
Results
Tim‐3 protein was over‐expressed in bladder cancer cells, tumor infiltrating lymphocytes and endothelial cells from patients with BUC. The expression levels of Tim‐3 were significantly correlated with advanced pathological grade and T stage. Moreover, another immune checkpoint molecule programmed death receptor‐1(PD‐1) was also over‐ expressed in BUC tissues and had a significant correlation with Tim‐3. Multivariate analysis showed that Tim‐3 expression, as well as PD‐1 expression was both independent predictors of disease‐free survival and overall survival in patients with BUC.
Conclusion
Tim‐3 over‐expression implies adverse clinical outcomes for BUC, which suggests it is a potential prognostic biomarker and a novel therapeutic target in BUC. J. Surg. Oncol. 2015; 112:430–435. © 2015 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26265374</pmid><doi>10.1002/jso.24012</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2015-09, Vol.112 (4), p.430-435 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1716942144 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism bladder urothelial carcinoma Case-Control Studies Female Follow-Up Studies Hepatitis A Virus Cellular Receptor 2 Humans Immunoenzyme Techniques Male Membrane Proteins - metabolism Middle Aged Neoplasm Grading Neoplasm Invasiveness Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging PD-1 Prognosis Survival Rate Tim-3 Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urothelium - metabolism Urothelium - pathology |
| title | T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A51%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=T-cell%20immunoglobulin%20mucin-3%20expression%20in%20bladder%20urothelial%20carcinoma:%20Clinicopathologic%20correlations%20and%20association%20with%20survival&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Yang,%20Meng&rft.date=2015-09-15&rft.volume=112&rft.issue=4&rft.spage=430&rft.epage=435&rft.pages=430-435&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.24012&rft_dat=%3Cproquest_cross%3E1716942144%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1715930399&rft_id=info:pmid/26265374&rfr_iscdi=true |